UnknownPhase 2NCT00531089

Rituximab in Patients With Relapsed or Refractory TTP-HUS

Studying Congenital thrombotic thrombocytopenic purpura

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Hamilton Health Sciences Corporation
Principal Investigator
Kathryn E Webert, E, MD
Hamilton Health Sciences Corporation
Intervention
Rituximab(drug)
Enrollment
60 enrolled
Eligibility
18 years · All sexes
Timeline
20072011

Study locations (11)

Collaborators

Canadian Apheresis Group · Hoffmann-La Roche · McMaster University

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT00531089 on ClinicalTrials.gov

Other trials for Congenital thrombotic thrombocytopenic purpura

Additional recruiting or active studies for the same condition.

See all trials for Congenital thrombotic thrombocytopenic purpura

← Back to all trials